Abstracts tagged "Cardiovascular disease"

Abstract Number: 2689 • 2017 ACR/ARHP Annual Meeting
Troponinemia Independently Associates with Mortality in Systemic Sclerosis
Julie J. Paik¹, Debbie Choi¹, Fredrick M. Wigley², Laura K. Hummers³ and Ami A. Shah¹, ¹Johns Hopkins University, Baltimore, MD, ²Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD
Title: Troponinemia independently associates with mortality in systemic sclerosis Background/Purpose: Cardiac involvement is common in systemic sclerosis (SSc) and in the early asymptomatic stages, elevated…
Abstract Number: 803 • 2017 ACR/ARHP Annual Meeting
Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis
Helin Masyan, Sinem Nihal Esatoglu, Ayse Merve Celik, Vedat Hamuryudan, Hasan Yazici and Emire Seyahi, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: In addition to the occlusive vasculitis, hypertension and accelerated atherosclerosis are probably risk factors of the cardiovascular complications in Takayasu arteritis (TA). Although, management…
Abstract Number: 1484 • 2017 ACR/ARHP Annual Meeting
Association between Primary Sjogren’s Syndrome, Arterial Stiffness and Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis
Wai Chung Yong, Anawin Sanguankeo and Sikarin Upala, Bassett Medical Center, Cooperstown, NY
AbstractBackground/Purpose: In rheumatoid arthritis and systemic lupus erythematosus, cardiovascular disease is frequently a major cause of mortality or morbidity. Studies have shown that acute systemic…
Abstract Number: 2065 • 2017 ACR/ARHP Annual Meeting
Higher Urate Volume Measured By Dual Energy Computed Tomography Is Associated with Unfavourable Cardiovascular Risks in Patients with Gout
Sang Heon Lee¹, Hae-Rim Kim², Kyung-Ann Lee³ and Jin Wuk Hur⁴, ¹Division of Rheumatology, Department of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea, Republic of (South), ³Department of Nuclear medicine, Konkuk University Medical center, seoul, Korea, Republic of (South), ⁴Rheumatology, Eulji University College of Medcine, Seoul, Korea, Republic of (South)
Background/Purpose: Hyperuricemia and gout are associated with increased risk of cardiovascular disease. The aim of the study was to evaluate the correlation between cardiovascular risk…
Abstract Number: 2788 • 2017 ACR/ARHP Annual Meeting
The Risk of Major Toxicity with Aspirin for Primary Cardiovascular Prevention in Rheumatoid Arthritis Patients Using Nsaids: A Secondary Cohort Analysis of a Randomized Controlled Clinical Trial
Daniel H. Solomon¹, Peter Libby², Qiuquing Wang³, Katherine E Wolski⁴, Lisa M Wisniewski⁴, Neville Yeomans⁵, Michael Lincoff⁶, Steven E Nissen⁷ and M. Elaine Husni⁸, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Cardiology, Brigham and Women's Hospital, Boston, MA, ³Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁵Western Sydney Medical School, Sydney, Australia, ⁶Cardiology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: There are relatively clear guidelines for the use of low dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit…
Abstract Number: 870 • 2017 ACR/ARHP Annual Meeting
Detection of Left Ventricular Regional Function in Rheumatoid Arthritis Patients without Cardiac Symptons, As Assessed By Feature Tracking Cardiac Magnetic Resonance Imaging
Hitomi Kobayashi¹, Yasuyuki Kobayashi², Isamu Yokoe³, Akiyuki Kotoku⁴, Atsuma Nishiwaki⁵, Kaita Sugiyama⁶, Noboru Kitamura⁵ and Masami Takei⁵, ¹Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ³Rheumatology, Kyoundo Hospital, Sasaki Institute, Tokyo, Japan, ⁴Advanced Biomedical Imaging Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁵Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ⁶Nihon University School of Medicine, Tokyo, Japan
Background/Purpose: Cardiac involvements cause of morbidity and mortality globally in rheumatoid arthritis (RA). Myocardial disease is typically clinically silent, only manifesting as myocardial dysfunction after…
Abstract Number: 1485 • 2017 ACR/ARHP Annual Meeting
Association between Primary Sjogren’s Syndrome, Cardiovascular and Cerebrovascular Events: A Systematic Review and Meta-Analysis
Wai Chung Yong, Anawin Sanguankeo and Sikarin Upala, Bassett Medical Center, Cooperstown, NY
AbstractBackground/Purpose: Studies have demonstrated that acute systemic inflammation and chronic systemic vasculitis are associated with endothelial dysfunction and atherosclerotic plaque formation, subsequently leading to cardiovascular…
Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Sarah Keller¹, Sharan K. Rai², Na Lu¹, Amar Oza³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…
Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
MaryAnn Zhang¹, Jun Liu², Eun Ha Kang³, Rishi J. Desai⁴, Tuhina Neogi⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…
Abstract Number: 871 • 2017 ACR/ARHP Annual Meeting
Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease
Katherine P. Liao¹, Gabrielle Cremone², Ethan Lam², Zhi Yu¹, Jon M. Hainer³, Victoria Morgan³, Courtney Bibbo³ and Marcelo Di Carli³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Nuclear Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with DM have increased coronary microvascular dysfunction (CMD) compared to the general population, leading to higher rates of cardiac death despite normal perfusion…
Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 2178 • 2017 ACR/ARHP Annual Meeting
Metabolic Osteoarthritis: Relation of Cardiovascular Disease and Diabetes to Knee Osteoarthritis
Laura Kuusalo¹, David T. Felson², Carrie Brown³, Cora E. Lewis⁴, James Torner⁵ and Tuhina Neogi², ¹University of Turku and Turku University Hospital, Turku, Finland, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Boston University School of Public Health, Boston, MA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of Iowa, Iowa City, IA
Background/Purpose: Metabolic changes or low-grade inflammation related to cardiovascular disease (CVD) and diabetes have been hypothesized to contribute to the development of OA. Prior studies…
Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Geraldo Castelar-Pinheiro¹ and Aleksandra Turkiewicz³, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
Abstract Number: 964 • 2017 ACR/ARHP Annual Meeting
Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages
Andrew Maidhof¹, Allison B. Reiss^1,2, Lora J. Kasselman², Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Lois Bonnetti¹, Melissa Fazzari², Joshua DeLeon¹ and Steven E. Carsons^1,2, ¹NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ²NYU Winthrop University Hospital, Winthrop Research Institute, Mineola, NY
Background/Purpose: Although the risk of atherosclerotic cardiovascular disease and abnormalities in cholesterol transport have been demonstrated in rheumatoid arthritis (RA), lupus (SLE) and, to a…
Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
M. Elaine Husni¹, Vandana Rai², Marcia Leon Rabanal³ and Unnikrishnan Chandrasekharan⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…

« Previous Page
1
…
8
9
10
11
12
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.